Berna Öksüzoğlu

5.6k total citations
198 papers, 1.7k citations indexed

About

Berna Öksüzoğlu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Berna Öksüzoğlu has authored 198 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Oncology, 86 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Berna Öksüzoğlu's work include HER2/EGFR in Cancer Research (24 papers), Cancer Treatment and Pharmacology (23 papers) and Gastric Cancer Management and Outcomes (20 papers). Berna Öksüzoğlu is often cited by papers focused on HER2/EGFR in Cancer Research (24 papers), Cancer Treatment and Pharmacology (23 papers) and Gastric Cancer Management and Outcomes (20 papers). Berna Öksüzoğlu collaborates with scholars based in Türkiye, United States and Spain. Berna Öksüzoğlu's co-authors include Nurullah Zengin, Burçin Budakoğlu, Necati Alkış, Nuriye Özdemir, İbrahim Türker, Arife Ulaş, Cengiz Karaçin, Hüseyin Abalı, Öznur Bal and Ülkü Yalçıntaş Arslan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Berna Öksüzoğlu

175 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Berna Öksüzoğlu Türkiye 22 843 681 262 257 243 198 1.7k
Norbert Marschner Germany 25 1.3k 1.5× 649 1.0× 258 1.0× 349 1.4× 407 1.7× 153 2.2k
Nurullah Zengin Türkiye 21 787 0.9× 479 0.7× 300 1.1× 175 0.7× 187 0.8× 160 1.5k
Pınar Saip Türkiye 21 606 0.7× 520 0.8× 337 1.3× 354 1.4× 288 1.2× 115 1.6k
Daris Ferrari Italy 24 836 1.0× 585 0.9× 409 1.6× 187 0.7× 243 1.0× 69 1.7k
S. V. S. Deo India 26 900 1.1× 546 0.8× 674 2.6× 525 2.0× 396 1.6× 232 2.3k
Alice Nennecke Germany 14 1.2k 1.4× 521 0.8× 358 1.4× 203 0.8× 198 0.8× 36 2.0k
Florian Scotté France 27 1.1k 1.3× 459 0.7× 395 1.5× 155 0.6× 298 1.2× 131 2.0k
Hee Kyung Ahn South Korea 31 1.2k 1.5× 949 1.4× 345 1.3× 233 0.9× 369 1.5× 171 2.7k
Gianmauro Numico Italy 28 1.1k 1.4× 776 1.1× 531 2.0× 399 1.6× 569 2.3× 115 2.6k
Hugues Bourgeois France 20 1.4k 1.7× 429 0.6× 384 1.5× 415 1.6× 305 1.3× 101 2.1k

Countries citing papers authored by Berna Öksüzoğlu

Since Specialization
Citations

This map shows the geographic impact of Berna Öksüzoğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berna Öksüzoğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berna Öksüzoğlu more than expected).

Fields of papers citing papers by Berna Öksüzoğlu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berna Öksüzoğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berna Öksüzoğlu. The network helps show where Berna Öksüzoğlu may publish in the future.

Co-authorship network of co-authors of Berna Öksüzoğlu

This figure shows the co-authorship network connecting the top 25 collaborators of Berna Öksüzoğlu. A scholar is included among the top collaborators of Berna Öksüzoğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berna Öksüzoğlu. Berna Öksüzoğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mirallas, Oriol, et al.. (2025). Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. The Lancet Regional Health - Europe. 54. 101317–101317. 1 indexed citations
2.
Özdemir, Nuriye, et al.. (2025). Effect of a ChatGPT-based digital counseling intervention on anxiety and depression in patients with cancer: A prospective, randomized trial. European Journal of Cancer. 221. 115408–115408. 6 indexed citations
3.
4.
Karaçin, Cengiz, Zuhat Urakçı, Ali Yılmaz, et al.. (2024). Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. 20(4). 207–214.
5.
Karaçin, Cengiz, et al.. (2023). Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. Journal of Oncology Pharmacy Practice. 32(2). 379–382. 5 indexed citations
6.
Ateş, Öztürk, et al.. (2022). Platelet-to-Lymphocyte Ratio as an Indicator to Predict Decreased Carbon Monoxide Diffusion of the Lung in Patients with Testicular Cancer. Journal of College of Physicians And Surgeons Pakistan. 32(3). 369–372. 1 indexed citations
7.
Ateş, Öztürk, et al.. (2022). Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.. PubMed. 26(4). 1398–1404. 2 indexed citations
8.
Karaçin, Cengiz, et al.. (2022). Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer. Journal of College of Physicians And Surgeons Pakistan. 32(11). 1501–1502.
9.
Ateş, Öztürk, et al.. (2021). Clinical Outcomes and Prognostic Factors in HER-2 Positive Breast Cancer with Brain Metastasis: A Single-centre Experience. Journal of College of Physicians And Surgeons Pakistan. 31(2). 166–170. 5 indexed citations
10.
Güven, Deniz Can, et al.. (2021). Adjuvant Treatment with Paclitaxel Plus Trastuzumab for Node-Negative Breast Cancer: Real-Life Experience. Future Oncology. 18(3). 323–331. 3 indexed citations
11.
Karaçin, Cengiz, et al.. (2020). Prognostic Importance of Metastatic Site in Intermediate-risk Group Metastatic Renal Cell Cancer Treated with Tyrosine Kinase Inhibitors. Journal of College of Physicians And Surgeons Pakistan. 30(6). 590–594. 3 indexed citations
12.
Bilgetekin, İrem, et al.. (2020). Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel. Journal of College of Physicians And Surgeons Pakistan. 30(8). 815–821. 1 indexed citations
13.
Esin, Ece, et al.. (2019). Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies. SHILAP Revista de lepidopterología. 5(3). 96–99. 1 indexed citations
14.
Budakoğlu, Burçin, Kadri Altundağ, Sercan Aksoy, et al.. (2018). Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.. PubMed. 19(4). 872–8. 3 indexed citations
15.
Esin, Ece, et al.. (2017). Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer. SHILAP Revista de lepidopterología. 4(1). 11–14.
16.
Özdemir, Nuriye, Sercan Aksoy, Mehmet Alı Nahıt Şendur, et al.. (2014). Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.. PubMed. 18(4). 831–7. 3 indexed citations
17.
Türker, İbrahim, Sercan Aksoy, Berna Öksüzoğlu, et al.. (2014). Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.. PubMed. 18(3). 585–93. 2 indexed citations
18.
Üyetürk, Ümmügül, et al.. (2013). Isolated ovarian metastasis of gastric cancer: Krukenberg tumor. Współczesna Onkologia. 6(6). 515–519. 7 indexed citations
19.
Çetin, Bülent, Mustafa Beneklı, Faysal Dane, et al.. (2013). Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Breast Care. 8(1). 67–70. 18 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norbert Marschner Breakdown of academic impact, for papers by Nurullah Zengin Breakdown of academic impact, for papers by Pınar Saip Breakdown of academic impact, for papers by Daris Ferrari Breakdown of academic impact, for papers by S. V. S. Deo Breakdown of academic impact, for papers by Alice Nennecke Breakdown of academic impact, for papers by Florian Scotté Breakdown of academic impact, for papers by Hee Kyung Ahn Breakdown of academic impact, for papers by Gianmauro Numico Breakdown of academic impact, for papers by Hugues Bourgeois
Rankless by CCL
2026